Targeting Other Modifiable Risk Factors for the Prevention of Heart Failure: Diabetes, Smoking, Obesity, and Inactivity
Purpose of Review
Prevention and reduction of risk factors is imperative in the battle against the heart failure epidemic. In this report, we update prior reviews with a focus on the modifiable risk factors of diabetes, smoking, obesity, and inactivity with regard to epidemiology, pathophysiology, management, and therapeutic options.
While the incidence of diabetes is rising, recent trials suggest options for diabetic patients to prevent cardiovascular morbidity, mortality, and heart failure, with several more trials underway. We highlight several novel agents including sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor antagonists. Tobacco smoking significantly increases the risk for heart failure, and recent data show early cessation may be beneficial. Education, support mechanisms, and weaning tools are useful, but some patients may benefit from behavioral counseling and even pharmacotherapy. Obesity is well recognized for its role in the development of heart failure and contributes to standard cardiovascular risk factors, left ventricular hypertrophy, sleep apnea, and metabolic syndrome. Lifestyle changes are vital to impacting this condition and thus rely heavily on patient motivation and compliance. Newer medications for assistance with weight loss have been approved, while bariatric surgery may be necessary for some. Specific effects of physical activity on heart failure prevention are not well delineated and may differ for patients with diabetes.
Extensive efforts in patient education on self-management of their health, prevention and control of risk factors will be the ultimate solution to decreasing the incidence of heart failure in the future.
KeywordsHeart failure Diabetes Smoking Tobacco use Obesity Prevention
Compliance with Ethical Standards
Conflicts of Interest
Dr. Gong and Dr. Hall declare no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not describe studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 5.Arnold JM, Howlett JG, Dorian P, et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol. 2007;23:21–45.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.• Heart Failure Society of America. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail. 2006;12:10–38. The 2006 Heart Failure Society of America comprehensive practice guideline addresses the full range of evaluation, care, and management of patients with HF.CrossRefGoogle Scholar
- 7.Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46:e1–82.CrossRefPubMedGoogle Scholar
- 8.Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115–40.CrossRefPubMedGoogle Scholar
- 9.Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2008;117:2544–65. This statement from the American Heart Association addresses the identification, increasing incidence, and prevention of heart failure through aggressive implementation of evidencebased management of risk factors.CrossRefPubMedGoogle Scholar
- 10.Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writingommittee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154–235.CrossRefPubMedGoogle Scholar
- 18.American Diabetes Association. Statistics About Diabetes 2017 [cited 2017 October 2]. Available from: http://www.diabetes.org/diabetes-basics/statistics/?loc=db-slabnav.
- 49.Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6:395–402.CrossRefPubMedGoogle Scholar
- 50.Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731.CrossRefPubMedPubMedCentralGoogle Scholar
- 51.Varas-Lorenzo C, Margulis AV, Pladevall M, Riera-Guardia N, Calingaert B, Hazell L, et al. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc Disord. 2014;14:129.CrossRefPubMedPubMedCentralGoogle Scholar
- 61.Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes 2008 [cited 2017 October 2]. Available from: https://www.fda.gov/downloads/Drugs/.../Guidances/ucm071627.pdf.
- 64.Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369–84.CrossRefPubMedGoogle Scholar
- 66.Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 2017;136:249–59.CrossRefPubMedPubMedCentralGoogle Scholar
- 68.US Department of Health and Human Services. FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) 2017 [cited 2017 October 2]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm557507.htm.
- 73.Centers for Disease Control and Prevention. Smoking & Tobacco Use - Data and Statistics 2017 [cited 2017 October 2]. Available from: https://www.cdc.gov/tobacco/data_statistics/.
- 79.Plesner LL, Dalsgaard M, Schou M, et al. The prognostic significance of lung function in stable heart failure outpatients. Clin Cardiol. 2017;40:1145-1151.Google Scholar
- 80.Centers for Disease Control and Prevention. Quitting smoking among adults—United States, 2001-2010. MMWR Morb Mortal Wkly Rep. 2011;60:1513–9.Google Scholar
- 81.Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006103.Google Scholar
- 82.Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63.CrossRefPubMedGoogle Scholar
- 84.Centers for Disease Control and Prevention. Adult obesity facts 2017 [cited 2017 October 2]. Available from: https://www.cdc.gov/obesity/data/adult.html.
- 85.Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society. J Am Coll Cardiol. 2014;63:2985–3023.CrossRefPubMedGoogle Scholar
- 89.Salehi-Abargouei A, Maghsoudi Z, Shirani F, Azadbakht L. Effects of Dietary Approaches to Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases--incidence: a systematic review and meta-analysis on observational prospective studies. Nutrition. 2013;29:611–8.CrossRefPubMedGoogle Scholar
- 92.Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002;156:1070–7.CrossRefPubMedGoogle Scholar
- 93.Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society. Circulation. 2014;129:S102–38.CrossRefPubMedGoogle Scholar